Please login to the form below

Not currently logged in

Cancer Research Horizons and the Karolinska Institutet announce five-year strategic partnership

The collaboration will aim to accelerate the translation of cancer research into clinical practice


Cancer Research Horizons – Cancer Research UK’s newly launched innovation engine – and research-led medical university, the Karolinska Institutet, have announced a five-year strategic partnership aiming to accelerate the translation of academic cancer research into improved treatments for patients.

The partners share a long-term strategy of promoting and supporting industry collaborations, facilitating the generation of new scientific discoveries that can be rapidly translated into clinical practice.

Tony Hickson, chief executive officer for Cancer Research UK and Cancer Research Horizons, said: “Not enough promising treatments are reaching cancer patients fast enough. In order to maximise patient benefit from the world-class research we fund, we need to accelerate its translation into clinical practice.

“But we can’t do this alone and need expert partners like the Karolinska Institutet to join us in our efforts to beat cancer.

Under the terms of the collaboration, the partners have made commitments to several joint activities including research collaborations and funding initiatives, theme-based alliances, mutual access to facilities, expertise and tools, as well as joint events and training programmes.

Accessing each other’s networks and collaboration partners will also be a major focus of the partnership, enabling the validation and translation of novel targets and mechanisms.

Through the partnership, Karolinska Institutet researchers will also be able to access the Cancer Research Horizons AstraZeneca Antibody Alliance Lab to use AstraZeneca’s phage display technology and associated technologies to undertake drug discovery research on novel cancer targets.

Martin Bergö, academic vice president for research said: “We are particularly excited by the opportunities that will arise from our new partnership with Cancer Research Horizons when it comes to realising our ambitions to translate basic and clinical research knowledge into meaningful therapies for cancer patients.”

Earlier this month, Cancer Research Horizons announced it was extending its strategic drug discovery alliance with Newcastle University and Astex Pharmaceuticals.

The agreement will extend the current alliance between the three parties by a further five years and will continue to focus on the discovery of potential new cancer drugs with associated biomarkers.

Under the terms of the agreement, Astex retains the right to an exclusive worldwide licence to take the most promising projects forward into pre-clinical and clinical drug development, with Cancer Research Horizons and Newcastle University eligible to receive milestone and royalty payments on any compounds that make it into clinical development and onto the market.

Article by
Emily Kimber

30th November 2022

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...